Noom Med's microdose GLP-1Rx program has an introductory first-month rate and a higher ongoing refill rate—$170.67/month effective over 12 months. We break down the cash-pay structure, compare it to alternatives, and explain what's included.

What is the average weight loss on tirzepatide in the first month at a microdose? The PlexusDx study reports what 57 patients recorded 14 to 35 days after starting 1 to 2 mg a week, including how many lost nothing. Here is the full picture, with its limits.

The PlexusDx study looked back at 60 adults who started compounded injectable tirzepatide at 1 to 2 mg a week and reports what their records showed at about 3, 7 and 9 weeks. Every number carries its group size and its window. Here is what the study can and cannot tell you.

The PlexusDx microdose tirzepatide study calls its findings hypothesis-generating. That is a promise about what the study can and cannot say. Here are six ideas, each in two plain sentences: sample size, time window, comparison group, self-report, completer bias and confidence interval.

A study is only as good as the records it sets aside. The PlexusDx microdose tirzepatide study started with 274 candidate records and ended with 60 patients. This article walks through every cut, why 93 eligible weights became 84 window records, and what was never estimated or filled in.

The labeled starting dose of tirzepatide is 2.5 mg a week. The PlexusDx study followed 60 adults who were new to GLP-1 medicines, had a BMI of 27 or higher, and started at 1 to 2 mg a week. Here is who was in the study, what the label says, and who makes the call.

Tirzepatide side effects at 1 to 2 mg a week: what 58 patients in the PlexusDx study said at their first check-in, what the FDA label warns about at any dose, and why routine check-ins are not the same as adverse-event surveillance.

A microdose of tirzepatide is not a medical term. In the PlexusDx study of 60 patients it meant a total weekly dose of 1 or 2 mg of injectable tirzepatide, below the usual 2.5 mg starting dose. Here is what that means, what it does not mean, and who decides.

Searches for how to microdose tirzepatide usually want a schedule. Doses are set by a licensed prescriber, not a blog. What we can share is how the program in the PlexusDx study was set up: 1 or 2 mg total per week, who set the dose, and how patients were followed.

Henry Meds offers real maintenance options — oral and microdose semaglutide — with prepaid terms attached. We map the tiers, the commitments, and the alternatives.

Standard-dose compounded semaglutide and tirzepatide are designed for stronger, more traditional weight loss support, while microdose GLP-1 protocols offer a gentler, lower-dose approach for patients who want gradual appetite control with potentially improved tolerability.

Many people ask if 1.25 mg of tirzepatide is a microdose and whether it works. Here is what the label says, what the PlexusDx study of 60 patients found for people who started at 1 mg a week, and why the study cannot answer the 1.25 mg question directly.

Taking tirzepatide twice a week is a schedule, not a dose. The label is once weekly. In the PlexusDx study, 4 of 60 patients started at 1 mg twice a week (2 mg a week total). Here is the difference between how often you inject and how much you get, and why only a prescriber should change either.

A tirzepatide results timeline, week by week, from two separate sources: what 60 patients on 1 to 2 mg a week reported in the PlexusDx study at about 3, 7 and 9 weeks, and what full-dose clinical trials of the FDA-approved product reported over 72 weeks. Kept apart, on purpose.

Eden advertises $99/mo semaglutide and $199/mo tirzepatide, but a required $99/mo membership makes the true all-in cost $198 and $298 (verified July 2026). We map those numbers against the PlexusDx Weight Management Protocol lineup ($129/mo to $349/mo) and walk the annualized cost math.

PA stuck on Wegovy, Zepbound, or Foundayo? The bridge options that won’t complicate your approval — LillyDirect from $299/mo, NovoCare from $149/mo, and the PlexusDx Microdose GLP-1 Protocol at $129/mo flat with no commitment.

MEDVi vs Gala GLP-1 vs PlexusDx compared on verified 2026 pricing, compounded vs FDA-approved status, cancellation rules, and where a genetic baseline changes the dose decision before week one.

The honest list of GLP-1 options under $200/mo in April 2026 is much shorter than the ads suggest. PlexusDx Microdose GLP-1 Protocol at $129/mo flat is the lowest under-$200 option in this comparison, with PlexusDx Semaglutide Injection at $189/mo month-to-month (or $149/mo on the 6-month plan) as the lowest weekly compounded semaglutide path. FDA-approved Foundayo and the Wegovy pill start at $149/mo at lower doses but escalate with dose; most other “$199 GLP-1” ads are first-month-only promos that jump to $249–$349 on refill.

There is no microdose Zepbound® product. The lowest labeled dose is 2.5 mg a week, and a pen delivers one fixed dose. When people say microdose Zepbound they usually mean staying at 2.5 mg longer, or compounded tirzepatide at a smaller amount, which is not Zepbound®. Here is the difference.

Microdose GLP-1 protocols use lower-than-standard doses of GLP-1 receptor agonists titrated by a clinician for better tolerability. This article covers what microdose means, the rationale, and the PlexusDx Microdose GLP-1 protocol inside the Weight Management Protocols collection.